MIAMI, November 19, 2025 — Leads & Copy — Longeveron Inc. (NASDAQ: LGVN), a biotechnology firm focused on cell therapies, will present findings from its CLEAR MIND study at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) in San Diego, CA, December 1-4, 2025.
The company’s submission, titled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study,” has been selected for a poster presentation.
Joshua Hare, Co-founder, Chief Science Officer and Executive Chairman of Longeveron, expressed enthusiasm about presenting laromestrocel data at the forum, stating that the findings could provide mechanistic and clinical insights into cellular therapy for Alzheimer’s disease.
The poster presentation is scheduled for Monday, December 1, 2025, from 3:00 p.m. PT to Tuesday, December 2, 2025, 5:30 p.m. PT, during Poster Session 1, Section 11, which focuses on new therapies and clinical trials.
Laromestrocel (Lomecel-B®), Longeveron’s lead investigational product, is derived from mesenchymal stem cells (MSCs) isolated from the bone marrow of healthy adult donors. MSCs are essential for tissue repair, responding to injury or disease by secreting immunomodulatory and regenerative bioactive factors. The company believes laromestrocel has multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, making it applicable for various rare and aging-related diseases.
Longeveron is currently focusing on three pipeline indications for laromestrocel: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). The FDA has granted several designations to laromestrocel, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for the HLHS program, as well as Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the AD program.
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Joshua Hare
Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron
Source: Longeveron Inc.
